BioSyent Inc. (CVE:RX - Free Report) - Equities research analysts at Bloom Burton dropped their FY2025 earnings per share estimates for shares of BioSyent in a research report issued on Tuesday, May 20th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of $0.75 for the year, down from their prior forecast of $0.81. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share.
BioSyent Stock Performance
RX opened at C$11.70 on Thursday. The stock's 50 day simple moving average is C$10.81 and its 200-day simple moving average is C$11.06. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The stock has a market cap of C$133.82 million, a PE ratio of 18.99 and a beta of 0.93. BioSyent has a 1 year low of C$8.92 and a 1 year high of C$12.13.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
